Coronavirus (COVID-19) News
Filter News
Found 2,568 articles
-
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
11/1/2022
Moderna, Inc. announced that it has received approval from the Ministry of Health, Labour and Welfare in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222 in adults 18 years and older.
-
ScreenPro Reports a Major Increase in Positive Test Results
10/28/2022
ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") would like to share an internal report indicating the Company's Covid PCR (Polymerase Chain Reaction) testing has experienced a significant spike in positivity rates in their testing results in the film and production industry.
-
Canadian Cardiovascular Society Receives $1.6 million to Study Myocarditis and/or Pericarditis after mRNA COVID-19 Vaccination
10/27/2022
Dr. Howard Njoo, Canada's Deputy Chief Public Health Officer and Interim Vice-President of the Infectious Diseases Programs Branch, announced funding to support a pan-Canadian study of the clinical and functional outcomes of adults and children who experienced myocarditis and/or pericarditis after receiving an mRNA COVID-19 vaccination.
-
Pandemic Protect Deployed in Massachusetts as COVID-19 Cases Rise
10/27/2022
Quantgene, a medical intelligence firm specializing in precision medicine and advanced COVID-19 solutions, is now offering Pandemic Protect throughout Massachusetts as COVID-19 cases rise.
-
Therma Bright Receives New Billing Codes for Venowave Allowing for Reimbursement from Medicare, Medicaid, and Private Insurers
10/27/2022
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies
-
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
10/26/2022
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection.
-
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
10/26/2022
Bristol Myers Squibb announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia from the ongoing Phase 3 DAYBREAK open-label extension study in relapsing multiple sclerosis.
-
Early Data Indicate Gritstone’s Self-Amplifying mRNA Vaccine could Fill COVID-19 Gaps - Updated
10/25/2022
Data from two Phase I trials indicate Gritstone Bio's samRNA vaccine can safely induce a strong and durable immune response against COVID-19. -
Inotrem Announces That Its ESSENTIAL Phase II Study for the Treatment of Critically ill COVID-19 Patients Meets Its Primary and Key Secondary Endpoints
10/25/2022
Inotrem announced at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positive results for ESSENTIAL, its Phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress.
-
Understanding the Evolution of SARS-CoV-2 Could Be the Key to Treating It, According to Researchers at the UCSF QBI Coronavirus Research Group (QCRG)
10/25/2022
Researchers at the UCSF QBI Coronavirus Research Group have uncovered how the SARS-CoV-2 variants of concern differ in their ability to manipulate human cells on a molecular level during infection.
-
Naltrexone Demonstrates Promising Long COVID Application
10/20/2022
LOVE Pharma Co., the Company having announced its nonbinding Letter of Intent to acquire Naltrexone Therapeutics Inc., on October 11th, is pleased to share that Naltrexone has been identified to show promise in treatment of long COVID.
-
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
10/19/2022
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization for mRNA-1273.222 as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, who have previously received at least a primary vaccination course against COVID-19.
-
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
10/19/2022
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending a variation to the conditional marketing authorization to include a 25 µg two-dose series of Spikevax for active immunization to prevent coronavirus disease 2019 caused by SARS-CoV-2 in children 6 months to 5 years.
-
bioLytical Laboratories Inc. receives WHO PQ for its iStatis COVID-19 Antigen Home Test
10/18/2022
bioLytical Laboratories Inc., a global leader in rapid in-vitro medical diagnostics, announced it has received its WHO PQ for its self-test, the iStatis COVID-19 Antigen Home Test, allowing its immediate entry into international markets.
-
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
10/17/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Gavi, the Vaccine Alliance, have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022.
-
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage
10/14/2022
NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission on Thursday, October 13, 2022.
-
MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test
10/14/2022
MedMira Inc. announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test, the fastest SARS-CoV-2 Antigen test available.
-
Pfizer and BioNTech released early data Thursday morning from a Phase II/III trial assessing an Omicron-specific booster that showed it provided significant protection, confirming early research.
-
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
10/13/2022
Pfizer Inc. and BioNTech SE announced early data from a Phase 2/3 clinical trial evaluating the safety, tolerability, and immunogenicity of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.
-
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age
10/12/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has received emergency use authorization from the U.S. Food and Drug Administration for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents 6 to 17 years of age.